BioDelivery Sciences stock has surged in the past month because investors realize the potential for Bunavail, its recently FDA approved treatment for opioid dependency, says the company's CEO Dr. Mark Sirgo. Sirgo says the ability of Bunavail to stick on the inside of the cheek, unlike products that need to be kept in place under the tongue until they dissolve, is evolutionary because it allows patients to talk, swallow and go about normal daily activities while the medication is being consistently absorbed. Sirgo says the product has peak sales potential of $250M and will hit the market in late 2014.

undefined

More from Video

Why Starbucks Stock Is Being Pounded After Revealing 150 Store Closures

Why Starbucks Stock Is Being Pounded After Revealing 150 Store Closures

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Buick's $40,000 Tough-Looking Station Wagon Is a Worthy Driveway Addition

Buick's $40,000 Tough-Looking Station Wagon Is a Worthy Driveway Addition

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks

Trump's Tariff Attack Hasn't Brought Pain to These Hot Stocks